Clinical and health nutrition M&A in Europe

Why the European market is entering a new phase of consolidation

Clinical and health nutrition today constitute one of the most attractive segments of the European healthcare market. Driven by population aging, the rise in chronic disease, the growth of home care, and the emergence of new therapeutic approaches, these markets are seeing an acceleration in M&A activity.

For investors, industrial groups, and private equity funds, clinical nutrition offers a rare combination of structural growth, revenue recurrence, and high barriers to entry. Companies specializing in foods for special medical purposes (FSMP), enteral nutrition, oral nutritional supplements (ONS), dysphagia, or clinical biotics are now at the heart of consolidation strategies across Europe and North America.

A market driven by long-term demographic trends

The aging of the European population is profoundly reshaping patients' nutritional needs. Age-related malnutrition, sarcopenia, neurological conditions, and cancer are driving rising demand for specialized nutritional solutions.

At the same time, healthcare systems are pushing for earlier and more effective patient management in order to reduce hospital costs. This shift favors the development of prescribed or reimbursed clinical nutrition products, as well as home nutrition solutions.

In many European countries, FSMP products benefit from reimbursement mechanisms that generate recurring revenue streams that are relatively resilient to economic cycles. These characteristics naturally attract investors seeking defensive assets with durable growth prospects.

Clinical nutrition: a still-fragmented market

The European market remains dominated by a handful of major international players such as Danone, Nestlé Health Science, Abbott, and Fresenius Kabi. Beneath this layer of global leaders, however, lies a significant fabric of specialized companies generating between €5 million and €100 million in revenue.

These companies often hold particularly sought-after strategic assets:

• hospital listings;
• reimbursed products;
• regulatory expertise;
• established relationships with prescribers;
• scientific know-how;
• proprietary formulation portfolios.

This fragmentation creates particularly favorable conditions for build-up strategies and sector consolidation.

Dysphagia: a niche turned strategic

Among the most attractive segments is dysphagia, which affects patients with swallowing disorders.

Population aging, the rise in neurodegenerative disease, and post-stroke patient care are strongly driving demand for:

• medical thickeners;
• adapted beverages;
• texture-modified fortified foods;
• meals for hospitals and nursing homes.

This market has several characteristics particularly favorable to M&A activity:

• growth above that of the overall market;
• low level of consolidation;
• technical expertise that is difficult to replicate;
• strong complementarity with clinical nutrition activities.

Companies specializing in modified textures are now prime targets for groups seeking to strengthen their presence with healthcare institutions.

The rise of clinical biotics

The microbiome has become one of the most dynamic themes in health nutrition.

While the consumer probiotics market is highly competitive, clinical biotics have a much more defensible positioning. The most attractive companies are those developing:

• proprietary strains;
• robust clinical studies;
• specific medical indications;
• collaborations with healthcare professionals.

Applications include gastroenterology, oncology, metabolic health, and managing the side effects of medical treatments.

For acquirers, these companies represent an opportunity to access highly differentiated assets built on solid scientific foundations.

Women's health: a new frontier in specialized nutrition

Women's health is gradually establishing itself as one of the sector's most promising categories.

Demand is growing rapidly across several areas:

• fertility;
• pregnancy;
• postpartum;
• menopause;
• women's oncology.

Companies able to demonstrate measurable clinical benefits and to work with gynecologists, midwives, or oncologists hold a significant competitive advantage.

For investors, these companies often offer growth profiles superior to those seen in traditional clinical nutrition.

The emerging opportunity linked to GLP-1 treatments

The widespread arrival of GLP-1 therapies for weight management is opening up a new market with strong potential.

Patients on these therapies frequently face several nutritional challenges:

• reduced caloric intake;
• muscle mass loss;
• protein deficiencies;
• digestive issues.

This shift is creating significant opportunities for companies offering targeted nutritional solutions, particularly in medical proteins, lean mass preservation, or metabolic support.

Many observers already view GLP-1 companion nutrition as one of the sector's future growth drivers.

The most attractive geographic markets

Germany remains the largest European clinical nutrition market thanks to its structured reimbursement system and strong medical culture.

The United Kingdom is also of major interest, thanks to the NHS and the presence of specialized players holding strong positions in reimbursed products.

Italy and Spain offer a particularly rich pool of family-owned companies and SMEs likely to participate in consolidation strategies.

The Nordic countries stand out for their head start in aging, home care, and senior nutrition.

Lastly, the United States remains the world's largest market for medical nutrition, even though regulatory and commercial barriers there are higher.

What acquirers are looking for today

In the current environment, the most sought-after companies generally share several of the following characteristics:

• revenue between €5 million and €100 million;
• a portfolio of FSMP or prescription products;
• established reimbursement in one or more markets;
• an active prescriber network;
• differentiating clinical data;
• exposure to dysphagia, aging, or chronic disease;
• international expansion potential.

Companies combining scientific expertise, medical presence, and recurring revenue tend to command the highest valuations.

A decade of consolidation ahead

The European clinical nutrition market is entering a major transformation phase. The convergence of medical nutrition, preventive health, and therapeutic support is creating new growth and consolidation opportunities.

For investors and industrial players alike, the coming years are expected to see a multiplication of M&A transactions involving specialized, mid-sized players.

Companies able to provide clinical evidence, strong relationships with healthcare professionals, and solutions addressing the challenges of aging and chronic disease will be at the center of this dynamic.

In this context, clinical nutrition stands out as one of the most promising sectors in the European healthcare market.

Considering an acquisition, a sale, or a consolidation strategy in clinical nutrition?

The clinical nutrition, FSMP, dysphagia, clinical biotics, and women's health market is entering an unprecedented phase of consolidation. In an environment where regulatory, clinical, and industrial considerations are decisive, identifying the right targets, structuring transactions, and gaining access to specialized investors become key success factors.

RightLiens is an independent investment bank specializing in healthcare. It supports executives, entrepreneurs, industrial players, and investors in external growth transactions, divestitures, fundraising, and build-up strategies, both in France and internationally. Its approach combines financial expertise, sector understanding, and a network of specialized healthcare investors.

Whether you lead a clinical nutrition company, a health nutrition business, a home care player, or a company active in dysphagia or the microbiome, the RightLiens team can support you with:

• identifying acquisition targets in Europe and the United States;
• preparing and executing M&A transactions;
• build-up strategies;
• fundraising and growth financing;
• succession and divestiture transactions.

To discuss your project confidentially, contact RightLiens Healthcare Investment Bank directly. RightLiens is a committed investment bank that places sustainable value creation, impact, and sector expertise at the heart of every transaction.